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Herein, we evaluate the potential of using a simple solvent granulation process to prepare a binary drug 
amorphous solid dispersion (ASD) containing two anti-HIV drugs, ritonavir and lopinavir. The drugs were 
granulated onto a mixture of lactose and microcrystalline cellulose, followed by drying to remove the solvent. 
The resultant granules were characterized and each drug was found to be X-ray amorphous. No crystallization 
was observed following storage for 1 month under accelerated stability conditions (40 °C and 75% relative 
humidity). The dissolution behavior of the compacted granules was compared with the marketed formulation. 
The dissolution rate of ritonavir was found to be significantly retarded relative to the commercial product when 
the two drugs were co-granulated. However, comparable release could be achieved when each drug was in-
dividually granulated, followed by combination and compaction. The solvent granulation approach may be a 
viable method to make ASDs of low dose drugs with low crystallization tendencies. 
1. Introduction 
With an increase in the number of therapeutically active compounds 
exhibiting low water solubility, formulation strategies such as amor-
phization, salt formation, complexation, micellization, are increasingly 
employed to improve solubility and bioavailability (Aisha et al., 2012; 
Frank et al., 2012a; Loftsson, 2017; Takano et al., 2010). Among these, 
amorphous formulations, which typically yield a higher solubility (su-
persaturated solution) and dissolution rate as compared to the crys-
talline state are often a preferred strategy (Hancock and Zografi, 1997). 
Other approaches such as complexation or micellar solubilization can 
increase the drug concentration in solution but do not necessarily result 
in supersaturation and thus will not improve the flux across a biological 
membrane (Frank et al., 2012b; Raina et al., 2015); flux has been shown 
to depend on the supersaturation gradient across the membrane rather 
than the concentration difference (Borbás et al., 2016). Since amor-
phous drugs tend to transform to the more stable crystalline phase upon 
storage, appropriate polymers are usually added to form a molecular 
dispersion, thereby decreasing the molecular mobility of the system, 
increasing the glass transition temperature (Tg), and providing kinetic 
stabilization against crystallization (Kothari et al., 2015; Prasad et al., 
2014). 
While there have been many investigations of amorphous solid 
dispersions (ASD) containing a single drug, an emerging scenario is the 
formulation of co-amorphous dosage forms. For these systems, there is a 
need to understand the impact of having more than one drug in the 
formulation. Multidrug formulations are becoming increasingly pre-
valent for diseases such as human immunodeficiency and hepatitis C 
viral infections, whereby treatment regimens require the administration 
of multiple drugs. These formulations either take advantage of a sy-
nergistic effect of the two drugs (Zhang et al., 2000) or improve the 
absorption of one drug by including another compound that interacts 
with and inhibits the efflux transporters or to inhibit metabolic enzymes 
(Drewe et al., 1999). Even though a multiple drug regimen can be 
achieved by simultaneous administration of separately formulated 
drugs, it may be preferable to co-formulate two or more drugs as fixed 
dose combinations (FDC) to improve patient compliance. A number of 
such FDC dosage forms are marketed including Kaletra® (lopinavir/ri-
tonavir), Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fuma-
rate) and Harvoni® (sofosbuvir/ledipasvir). Some of these FDC products 
contain drugs that are crystalline in nature (e.g. Coartem®) while others 
have drugs that are formulated as amorphous solids to take advantage 
of their improved bioavailability, for example lopinavir and ritonavir. 
Recently, attention has been directed towards drug-drug co-amorphous 
systems wherein many combinations have been found to give a dis-
solution and physical stability advantage over the individually 
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formulated compounds. One example is naproxen which, though gen-
erally resistant to amorphization, could be made amorphous by mixing 
with indomethacin (a drug in the same therapeutic class) (Löbmann 
et al., 2011). Improved stability of the co-amorphous system can be due 
to the formation of favorable intermolecular interactions between the 
two drugs thereby resulting in a higher than expected Tg (Martinez 
et al., 2016). Alternatively, it may be due to interference of the nu-
cleation process as inferred in the case of nimodipine:nifedipine co-
amorphous blends wherein the Tg of the mixture was lower than ex-
pected but the system was nevertheless more resistant to crystallization 
(Knapik-Kowalczuk et al., 2018). However, in terms of dissolution as-
sessment, in many cases, comparisons are made between the co-amor-
phous system and the corresponding crystalline forms (Dengale et al., 
2014; Shayanfar and Jouyban, 2013; Tantishaiyakul et al., 2009). Oc-
casions wherein the dissolution performance is improved relative to 
that of the pure amorphous drug are usually seen in cases where the 
amorphous co-former is acidic and the drug is a base, hence salt for-
mation occurs, or the acidic component increases the solubility of the 
drug by modifying the micro-environmental pH of the solute–solvent 
interface (Fung et al., 2018). In other instances, the individual amor-
phous drug crystallized faster when compared to the co-amorphous 
mixture and thus the dissolution advantage can be attributed to kinetic 
factors (Allesø et al., 2009). However, it has been shown previously 
that, when two drugs are miscible and uncharged, the amorphous so-
lubility of each component in the mixture is invariably lower than that 
of the pure individual amorphous components due to a decrease in their 
chemical potential resulting from molecular level mixing (Alhalaweh 
et al., 2016; Trasi and Taylor, 2015a, 2015b). 
Amorphous intermediates are usually manufactured at commercial 
scale using one of two main methods namely solvent evaporation (ty-
pically spray drying) or hot melt extrusion (HME) (Paudel et al., 2013; 
Repka et al., 2008) whereby each process has both advantages and 
limitations. HME requires that the drug is chemically stable at the high 
processing temperature employed (typically greater than 120 °C) and 
possesses a melt temperature that allows processing with a stabilizing 
polymer. Spray drying requires organic solvents to dissolve both the 
drug and the polymer leading to issues with controlling residual solvent 
content, and high costs associated with solvent recycling. Another 
drawback of spray drying is that the resultant powder may have a low 
bulk density and can have high electrostatic charge which can make 
powder handling difficult (Murtomaa et al., 2004). Both of these ap-
proaches are cost intensive in the manufacturing sense with high capital 
equipment costs. Since many drugs for the treatment of infectious dis-
eases are used extensively in low-income countries, there is a need to 
develop more economical formulations and manufacturing approaches 
that can be performed in the developing countries. 
In this study, we have evaluated the possibility of developing an 
inexpensive manufacturing method to make amorphous solid disper-
sion formulations, wherein we studied the feasibility of formulating a 
fixed dose combination of lopinavir and ritonavir (Fig. 1) prepared 
using wet granulation/solvent impregnation. Various techniques in-
cluding X-ray powder diffraction, infrared spectroscopy and release 
testing were used to characterize the resultant formulations. 
2. Materials 
Lopinavir and ritonavir were obtained from ChemShuttle (Hayward, 
CA). Microcrystalline cellulose pH 101 (MCC) and anhydrous lactose 
were obtained from Sigma-Aldrich (St. Louis, MO). Dichloromethane 
(DCM) and methanol (MeOH) were obtained from Fisher Scientific 
(Pittsburgh, PA). Cros-carmellose sodium was sourced from FMC 
Biopolymer (Newark, DE). AluviaTM (Manufactured by Abbott GmbH & 
Co, Ludwigshafen, Germany) was obtained from an Indian pharma-
ceutical distributor. 
3. Methods 
3.1. Preparation of dispersions 
Small scale experiments. An excipient mixture consisting of a 1:1 wt 
blend of anhydrous lactose and MCC pH 101 was prepared by physical 
mixing using a vortex mixer. A 1:1 DCM:MeOH solution containing one 
or both of the drugs was then added to this mixture and granules were 
formed by mixing using a spatula. The two drug components were in-
itially used at the ratio present in the marketed formulations, i.e. 
200 mg LPV:50 mg RTV. Other ratios of the drugs were also subse-
quently studied to improve mechanistic understanding. 200 mg of LPV, 
50 mg RTV, and 250 mg of PVPVA were dissolved in 2–3 mL of 1:1 
DCM:MeOH and added to 1.5 g of 1:1 MCC:anhydrous lactose and 
mixed using a spatula. Formulations containing 5% w/w Span 20 
(which is also present in the marketed formulation), or 0.1% w/w 
Tween 80 were also prepared whereby the overall tablet weight was 
maintained at 2 g. The granules were dried overnight in a vacuum oven, 
followed by milling for 10 s in a cryogenic mill (6750 freezer mill, Spex 
Sampleprep, Metuchen, NJ) to form a powder. RTV and LPV wet 
granulated dispersions were also prepared by making granules con-
taining just one drug (1:1 drug:polymer ratio) using the following for-
mula, 50 mg RTV + 50 mg PVPVA + 400 mg excipients and 200 mg 
LPV + 200 mg PVPVA + 1000 mg excipients. Preparation of the 20:80 
drug:PVPVA dispersion was performed using a larger amount of ex-
cipient (3 g per tablet) as the base powder resulting in a total tablet 
weight of above 4 g. A summary of all formulations is provided in Table 
S1. 
The resultant ASD formulation was placed in a desiccator with a 
saturated solution of sodium chloride which provides a relative hu-
midity of 75%. The container was placed at 40 °C and samples were 
removed every 7 days and analyzed by XRPD to monitor crystallization. 
Bench-top granulation. Bench-top granulation experiments were also 
performed to verify that granules could be produced using more in-
dustrial-like processing equipment. A custom-made bench-top granu-
lator, described in detail previously, was used (Wikstrom et al., 2008). 
An excipient mixture consisting of 1:1 by weight blend of anhydrous 
lactose and MCC pH 101 was prepared using a V – blender. Sixty grams 
of this blend was placed in the granulator. A 1:1 DCM:MeOH solution 
containing both of the drugs (12 g LPV and 3 g RTV) and PVPVA (15 g) 
was then gradually added to the excipient blend using a peristaltic 
pump. The rate of solvent addition was 25 mL/min, and addition oc-
curred in < 4 min. The tip speed used was 94 m/sec. The solution was 
added until complete granulation of the powder occurred. The granules 
were sieved and dried overnight in a vacuum oven. The granules were 
subsequently assayed for their drug content confirming that a 10% drug 
loading was achieved. The granules were then characterized in terms of 
their Carr’s Index, Hausner ratio, angle of repose, and particle size 
(using sieve analysis). Tablets containing 150 mg of granules were 
prepared using a computer-controlled tablet press (Gamlen Ta-
bleting Ltd., Nottingham, UK) by direct compression. The granules were 
compacted with a target load of 500 kg at the speed of 120 mm/min 
using a 6 mm punch. The force-displacement data obtained during ta-
blet preparation was analyzed to obtain the maximum load applied to 
the tablet during the compression, detachment and ejection steps. The 
tablets were evaluated for their hardness (Vanderkamp-Benchsaver 
Series, Cary, NC) and friability (Vankel Friabilator, Cary, NC). Both the 
tests were performed as per the specifications in USP. 
3.2. X-ray powder diffraction (XRPD) 
The X-ray diffraction profiles of the powders were determined using 
a Rigaku SmartlabTM diffractometer (Rigaku Americas, Texas, USA) 
with a Cu-Kα radiation source and a D/tex ultra detector. Samples were 
loaded onto glass sample holders and powder patterns were obtained 
from 5 to 35° 2θ at a scan speed of 10°/min and a step size of 0.02°. The 
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Fig. 1. Molecular structures of ritonavir and lopinavir. 
voltage and current used were 40 kV and 44 mA respectively. 
3.3. Dissolution testing 
The dispersions prepared at small-scale containing 200 mg of LPV 
and 50 mg of RTV were weighed and made into a compact using an E-Z 
hydraulic press (International Crystal Laboratories, Garfield, NJ) at 500 
psi for 3 s before removing the pressure. Croscarmellose sodium (10 wt 
%) was added to ensure tablet disintegration. Compacts were prepared 
to improve wetting during dissolution testing as the powder had a 
tendency to float, and to provide a better comparison with the marketed 
formulation. Tablets were added to 250 mL of pH 6.8 10 mM phosphate 
buffer pH 6.8, maintained at 37 °C in a jacketed beaker and stirred with 
a magnetic stirrer at 150 rpm. Samples were removed at regular time 
intervals, filtered through a 0.45um PTFE syringe filter (Tisch 
Scientific, North Bend, OH) and analyzed by high performance liquid 
chromatography (HPLC) as described below. The dissolution of 
AluviaTM in pH 6.8 media was difficult to determine due to significant 
difficulty in filtering the dissolution medium. This was due to the for-
mation of a milky solution during dissolution indicating the formation 
of nanodroplets which clogged small pore size filters and passed 
through filters with a larger pore size. Dissolution was also carried out 
in 250 mL of 0.1 N HCl under the same conditions to mimic dissolution 
in gastric media. For this medium, AluviaTM tablet dissolution also 
could be determined. For the scaled-up granules, granules equivalent to 
100 mg of drug content were added to a dissolution media consisting of 
100 mL of 0.1 N HCl in a jacketed beaker maintained at 37 °C and 
stirred with a magnetic stirrer at 150 rpm. Samples were removed at 
regular time intervals and filtered through a 0.45 μm PTFE syringe filter 
(Tisch Scientific, North Bend, OH) and analyzed by HPLC. 
A pH shift dissolution experiment was performed on the marketed 
product by adding one tablet to 200 mL of 0.1 N HCl stirred at 150 rpm 
and held at 37 °C. After 30 min, the solution was neutralized with 
750 mg of NaOH (dissolved in 10 mL of water) and an additional 40 mL 
of 100mM pH 6.8 buffer was added and the dissolution was continued. 
The amorphous solubility of the each drug in 10 mM pH 6.8 phos-
phate buffer was determined by preparing a stock solution of 20 mg/mL 
of RTV or LPV in methanol and adding 100 µL of the solution to the 
buffer containing 10 µg/mL HPMC (to inhibit crystallization) with 
stirring at 37 °C. The solutions were then ultracentrifuged using an 
Optima L-100 XP ultracentrifuge (Beckman Coulter Inc., CA, USA) with 
a SW 41 Ti swinging bucket rotor attachment at 35,000 rpm at 37 °C. 
The supernatant containing the molecularly dissolved drug was then 
removed and analyzed using high performance liquid chromatography 
(see below). The resultant concentration was taken as the amorphous 
solubility. 
3.4. High performance liquid chromatographic (HPLC) analysis 
HPLC analysis was performed using an Agilent HPLC 1260 Infinity II 
system (Agilent Technologies, Santa Clara, CA) equipped with a diode 
array detector. The column used for analyzing the samples was a 
SunfireTM C-18 analytical column (3.0 mm × 150 mm, 3.5 µm, 100 Å) 
(Waters Corporation, Milford, MA). The mobile phase was an acetoni-
trile: water mixture at a ratio of 60:40 v/v and the flow rate was 
0.5 mL/min. The analysis was conducted at room temperature and the 
detection wavelength was 215 nm. The retention times for RTV and LPV 
were 3.9 and 4.5 min respectively. The concentration of the drug was 
determined from the area under the curve of the drugs by comparing to 
a standard curve prepared from a stock solution of the drugs, both of 
which had R2 values of 0.999. 
3.5. Fourier transform Infra-red (FTIR) analysis 
FTIR spectra of melt quenched RTV and LPV were obtained using a 
Golden Gate ATR accessory (Specac, Fort Washington, PA) installed in a 
Vertex 70 model IR Spectrophotometer (Bruker Optics, Billerica, MA). 
A total of 64 scans were averaged in the spectral range of 
400–4000 cm−1. The ATR unit, as well as the detector compartment, 
were kept continuously flushed with dry air. The spectra of the co-
amorphous systems were determined after mixing and melting 200 mg 
LPV and 50 mg RTV into a pellet. This pellet was then exposed to the 
0.1 N HCl dissolution media for 1 h and then dried. The surface of the 
pellet that was exposed to the acidic media was scraped and the powder 
analyzed to determine the change in drug ratio on the surface. 
4. Results 
4.1. XRPD analysis and stability testing 
X-ray diffractograms of the 200/50 LPV/RTV granules prepared 
with PVPVA showed an absence of crystalline peaks arising from either 
drug suggesting that the drugs were present in their amorphous form. 
Reference diffractograms of crystalline ritonavir, lopinavir, and a blend 
of lactose and MCC are shown in Figure S1. The Bragg peaks seen in 
Fig. 2, in the diffractograms of the granules, arise from lactose which is 
in its crystalline form in the granules. In contrast, a physical mixture of 
crystalline drugs and excipients at the same drug loadings yielded an 
XRPD pattern with clearly distinguishable drug crystalline peaks, for 
example there are several peaks appearing at values below 10° 2Θ that 
are due the presence of crystalline drugs; these are absent in the 
granules (Fig. 2). Storage of the granules under accelerated stability 
open dish conditions (40 °C/75%RH) for one month did not result in the 
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Fig. 2. XRPD profiles of the granules before and after storage at accelerated 
storage conditions for 4 weeks shows that there is no development of crystalline 
peaks characteristic of either drug, whereby peaks arising from each drug can 
be clearly seen in the physical mixture. 
prepared by solvent evaporation were resistant to crystallization for this 
time period. When the drugs were granulated individually with a blend 
of MCC and lactose, no crystallization was observed after storage under 
similar conditions for one month (Figure S2). 
4.2. Dissolution testing 
4.2.1. Dissolution in pH 6.8 buffer 
The dissolution of RTV and LPV granules formulated as a single 
component and as a co-granulated formulation was evaluated in both 
near-neutral and acidic media, focusing on the maximum extent of 
supersaturation achieved. Under near-neutral pH conditions, the crys-
talline solubility of RTV is 1.8 µg/mL and that of LPV is 2.9 µg/mL, 
hence the dissolution conditions are highly non-sink with respect to the 
crystalline solubility. Neither compound is ionized at pH 6.8. Further, 
the dissolution data represent the concentration of molecularly dis-
solved species whereby the samples have been filtered to remove any 
colloidal aggregates. The resultant values can be used to calculate the 
extent of supersaturation, which is considered important for enhancing 
the rate of membrane flux in vivo (Bevernage et al., 2013). As can be 
seen from Fig. 3, RTV granules dissolved to a maximum concentration 
of just below 30 µg/mL, while LPV granules reached a final con-
centration of around 20 µg/mL at the end of 2 h of dissolution when the 
drugs were granulated and dissolved individually. These concentrations 
are close to the amorphous solubility of these compounds in this 
medium i.e. 31 µg/mL and 19 µg/mL for RTV and LPV respectively. 
Thus the solutions are maximally supersaturated with relative 
Fig. 3. Dissolution profiles of ritonavir and lopinavir from granules when 
granulated individually and when co-granulated in pH 6.8 buffer. Horizontal 
lines indicates (a) lopinavir amorphous solubility and (b) ritonavir amorphous 
solubility. 
supersaturations (where relative supersaturation, S, is C/C* where C is 
the experimentally measured concentration and C* is the crystal solu-
bility) of ~17 and ~7 for RTV and LPV respectively. However, when 
the 200/50 LPV/RTV granules containing a co-granulated intimate 
mixture of the drugs were dissolved, the maximum concentrations of 
each drug achieved were considerably lower, with the RTV con-
centration reaching a plateau at 4–5 µg/mL, while the LPV concentra-
tion reached around 15 µg/mL. Correspondingly, the supersaturation 
ratio was reduced to a factor of only ~3 for RTV, while that of LPV was 
reduced slightly to 5. 
4.2.2. Dissolution in 0.1 N HCl 
RTV is a weakly basic drug with pKa values of 1.8 and 2.6 for the 
two thiazole moieties. Therefore, it is highly, although not completely, 
ionized at pH 1.2, resulting in increased solubility (Law et al., 2001). At 
pH 1.2 the solubility of crystalline RTV is ~0.4 mg/mL (Law et al., 
2001) and for dissolution experiments at pH 1.2, sink conditions with 
respect to crystalline solubility exist. Consequently, when the dissolu-
tion is performed in an acidic media, significantly more RTV is mole-
cularly dissolved relative to that in neutral media due to the higher 
solubility of the ionized form. The molecularly dissolved RTV con-
centration upon AluviaTM dissolution reached around 170 µg/mL at the 
end of 2 h while the LPV concentration remained close to its amorphous 
solubility (Fig. 4). LPV is un-ionized at this pH and therefore does not 
dissolve to a higher concentration relative to that observed in neutral 
media. Interestingly, despite the acidic dissolution medium providing 
sink conditions, the concentration of molecularly dissolved RTV at the 
end of the dissolution experiment is lower than expected indicating 
incomplete release; the expected final solution concentration if all of 
the RTV dissolved is 200 μg/mL. To determine the reason for this, a 
200 µg/mL solution of RTV was prepared in 0.1 N by dissolving RTV-
only granules and to this was added 0.8 mg/mL of LPV, prepared by 
dissolving LPV-only granules, and the system was stirred for one hour. 
The RTV free drug concentration after addition of LPV decreased by 
10% to around 180 µg/mL, indicating that the presence of LPV induced 
a small amount of RTV precipitation (data not shown). 
The release rate and extent of RTV from the tableted granules 
(where both RTV and LPV were co-granulated) was significantly lower 
than that from AluviaTM with the concentration being less than 100 µg/ 
mL after 2 h, while the LPV release rate and extent were comparable 
(Fig. 3). The scaled-up co-granulated system likewise showed a lower 
release profile than observed from AluviaTM (Figure S3). 
4.2.3. Effect of pH shift on dissolution 
When the marketed formulation was first dissolved in acidic media 
and the pH subsequently increased, we observed a rapid decrease in the 
RTV concentration to below 5 µg/mL (Fig. 5), which cannot be ac-
counted for by the modest dilution. The resultant level of super-
saturation is similar to that observed for RTV released from the co-
Fig. 4. Dissolution of Aluvia tablets and co-granulated LPV-RTV 50:50 drug:-
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Fig. 5. Concentration versus time profile following initial dissolution in acidic 
media (250 mL 0.1 N HCl) followed by an increase in solution pH to pH 6.8 after 
the 30 min time point. The RTV concentration is reduced due to a change in the 
ionization state of the drug, with precipitation, while the neutral LPV is only 
slightly impacted initially by the 25% dilution. 
granulated ASD under neutral conditions (Fig. 3). At first glance, it 
might be assumed that this rapid decrease upon pH shift is due to the 
generation of an initially high supersaturation due to a decrease in the 
extent of ritonavir ionization, followed by rapid crystallization. 
To better evaluate the crystallization tendency upon pH shift, this 
experiment was repeated in the absence of any excipients which can 
interfere with the ability to detect crystalline material, especially in-
soluble excipients such as MCC. Here, a solution containing 100 µg/mL 
RTV, and 400 µg/mL LPV, initially at pH 1.2 was neutralized by addi-
tion of NaOH to yield a final solution pH of 6.8. Following addition of 
NaOH, precipitation was observed. Some of the resultant suspension 
was ultracentrifuged, followed by analysis of the RTV and LPV con-
centrations in the supernatant. A portion of the remaining suspension 
was analyzed using a polarized light microscope to determine if crystals 
could be detected. The concentration of RTV in the supernatant 
dropped considerably following pH change, from 100 to less than 
20 µg/mL (Fig. 6). The LPV concentration also decreased. However, no 
crystals were observed in the precipitated solution (Fig. 6 inset). These 
observations support the precipitation of a non-crystalline form of ri-
tonavir following an increase in pH. However, this non-crystalline form 
has a lower solubility than amorphous RTV alone (which is around 
32 µg/mL, Fig. 3), suggesting that LPV and RTV are mixed together in 
the precipitate when both compounds are unionized, which leads to a 
reduction in the maximum supersaturation, as observed previously 
(Trasi and Taylor, 2015a, 2015b). Further these observations are in 
general agreement with the granule dissolution experiments, both for 
Fig. 7. Dissolution of LPV-RTV granules at 1:1 drug:polymer ratio in 0.1 N HCl 
in the presence of 0.1% Tween and 5% Span 20 in the formulation. 
the pH shift experiments shown in Fig. 5, and the single stage dis-
solution experiments on the co-granulated drugs shown in Fig. 3, 
whereby the RTV concentration at higher pH is considerably lower than 
the amorphous solubility of RTV alone. 
4.2.4. Effect of drug loading and surfactants on dissolution 
Various strategies were employed to improve the dissolution profile 
of the wet granulated dispersions, so that a better match to the com-
mercial product was achieved in terms of the molecularly dissolved 
drug concentrations in the stomach environment. First, the total drug 
loading (relative to polymer) was reduced from 50 wt% to 20 wt%. 
However, no overall improvement in release performance was achieved 
using this approach (data not shown). Next, addition of surfactants was 
evaluated; a surfactant is present in the commercial product and sur-
factants have been shown to improve release from amorphous for-
mulations (Mosquera-Giraldo et al., 2018). 
As shown in Fig. 7, the addition of surfactants in the dispersions did 
not aid in improving the dissolution rate of RTV. The addition of Tween 
resulted in a similar profile to in the absence of the surfactant, while the 
addition of Span 20, present in the marketed formulation, seemed to 
reduce the rate and extent of RTV release. Neither surfactant had an 
appreciable impact on LPV release. 
4.2.5. Effect of LPV:RTV ratio on release 
To better understand the reduced solution concentrations of RTV in 
the presence of LPV (i.e. when both drugs are in the same ASD), we also 
prepared and evaluated granules with differing ratios of LPV and RTV, 
Fig. 6. Change in the concentration of molecularly 
dissolved drug when the pH is shifted from 1.2 to 
6.8. Concentrations were determined following ul-
tracentrifugation to remove any precipitates. The 
inset shows the lack of birefringence of the observed 
drug precipitates indicating that precipitated mate-
rial is non-crystalline. The dilution factor was 25%. 
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Fig. 8. Dissolution of 50 mg RTV in 250 mL 0.1 N HCl for dispersions con-
taining differing ratios of LPV and RTV. 
namely 125:125 and 50:200 LPV:RTV, in addition to the marketed 
200:50 ratio. The dissolution of tablets made from these granules in 
0.1 N HCl, such that the amount of RTV added to the media was the 
same in all the samples, showed that RTV reaches its highest con-
centration when it is prepared at the ratio 50:200 LPV:RTV (Fig. 8). 
Thus, for a constant total amount of RTV, a lower ratio of LPV enables 
enhanced RTV dissolution from the amorphous co-granulated mixture. 
This observation confirms that the presence of LPV, intimately mixed 
with RTV as in the co-granulated ASDs retards RTV release. 
4.2.6. Effect of granulating the drugs separately 
A different approach employed to prepare the FDC tablets in an 
effort to improve the release profiles was to use individually granulated 
powders. In other words, granules with only one drug in the dispersion 
were prepared and then blended and compacted. Alternatively, bi-
layered tablets were prepared where the granules containing each drug 
were kept physically separated. As can be seen from Fig. 9, both of these 
approaches resulted in rapid RTV releases whereby the final con-
centrations achieved were similar to those seen for the AluviaTM for-
mulation. 
4.3. FTIR analysis to understand dissolution behavior 
The FTIR spectra of the two drugs are very similar (Fig. 10) with the 
main differences observed in the carbonyl spectral region of 
1575–1800 cm−1 where RTV has an additional peak at 1704 cm−1 
adjacent to the overlapping peaks at around 1630 cm−1. RTV also has 
two large peaks at 1229 and 878 cm−1 which are absent in LPV. When 
the two drugs are mixed and melt quenched together at a ratio of 
200:50 LPV:RTV, the peaks uniquely representative of RTV are hard to 
distinguish, presenting, for example, as a small shoulder at 1718 cm−1. 
Upon exposure to 0.1 N HCl and partial dissolution of the surface of the 
amorphous mixture, the intensity of the shoulder decreases and the 
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ratio of peaks at 1630 cm−1 and 1718 cm−1 increases from 7.7 to 11.2, 
indicating a preferential loss of RTV from the surface during dissolu-
tion. In general, the spectrum becomes slightly more LPV-like after 
partial dissolution with additional subtle changes in the peaks, as 
shown by the arrows in Fig. 9. Given that the ATR sampling metho-
dology is somewhat surface sensitive (Planinsek et al., 2006), these 
observations are consistent with surface enrichment of LPV due to 
preferential dissolution of RTV. This is also consistent based on mass 
balance considerations using the dissolution data under acidic condi-
tions where it is apparent that relatively more RTV dissolves than LPV. 
Consequently, the amount of LPV in the undissolved ASD increases 
relative to the amount of RTV. 
4.4. Properties of granules and tablets 
The properties of granules produced using the bench-top granulator, 
and tablets prepared from these granules, were evaluated. The angle of 
repose value of granules was found to be 36.2 ± 0.7°. The Carr’s Index 
and Hausner ratio values were 14.4 ± 3.5% and 1.17 ± 0.05 re-
spectively. Sieve analysis of granules indicated that more than 80% of 
the particles lie in the size range of 150–595 µm (Figure S4). The 
granules contained less than 1.5% of fines (particle size < 45 µm). The 
calculated span value of granules was 1.72. The drug load % was found 
to be 8.4% for LPV and 2% for RTV. For tablet preparation, the max-
imum loads applied during compression, detachment and ejection steps 
were 518.7 ± 0.7 kg, 19.1 ± 3.1 kg, and 87.6 ± 4.4 kg respectively. 
All tablets were found to be intact after the friability test, with a fria-
bility of 0.7%. The hardness of the tablets was 10.17 ± 0.53 kPa. These 
results indicate that this manufacturing approach leads to granules with 
acceptable flow properties that can be compressed into tablets of low 
friability and sufficient hardness. 
5. Discussion 
Wet granulation using organic solvents appears to be a possible 
alternative approach to HME and spray drying for preparing an amor-
phous dosage form of the slowly crystallizing compounds, RTV and 
LPV, albeit with certain caveats. Thus, the amorphous forms of the 
drugs were successfully generated by solvent granulation/impregna-
tion, and the resultant granules were found to be physically stable 
against crystallization. Moreover, granules with good flow and com-
pression properties could be produced using this approach. However, 
there are factors that need to be considered when drugs are formulated 
and produced using this approach. One consideration is the final size of 
the tablet, since a relatively large excipient mass is required for suc-
cessful granulation with the drug-polymer organic solvent solution to 
avoid formation of a sticky mass. Clearly important factors here include 
the dose of the drug, as well as the solubility of the drug and polymer in 
the solvent system employed. Thus, the wet granulation approach is 
Fig. 9. Dissolution from (200:50 LPV:RTV) tablets prepared by (a) mixing individually granulated RTV and LPV and then compressing into one tablet and (b) 
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Fig. 10. FTIR spectra of (a) pure amorphous RTV, (b) pure amorphous LPV, (c) 200:50 LPV:RTV melt quenched amorphous blend and (d) 200:50 LPV:RTV melt 
quenched amorphous blend after exposure to 0.1 N HCl for 1 h. 
likely to be best suited for low dose formulations, or those where the 
drug and polymer are highly soluble in the solvent system, allowing a 
lower volume of solvent to be used. This issue also can be potentially, at 
least partially, mitigated by using excipients with a higher solvent ad-
sorption capacity; preliminary experiments showed that using a higher 
amount of MCC enabled an increase in drug loading. Alternatively, 
fluid-bed granulation is also a possible alternative, where a larger vo-
lume of solvent is less of an issue due to rapid solvent evaporation, 
facilitating a decrease in the amount of excipients. Of course, the drug 
also must be resistant to crystallization during the solvent evaporation 
process. Hence, more slowly crystallizing compounds, such as those 
with higher molecular weights and more complex structures, are most 
suitable for this general approach. Additionally, adequate drying is 
required to remove the organic solvent used to dissolve the hydro-
phobic drugs. The use of organic solvents to dissolve the drug and mix 
with the polymer in a simple manufacturing process is not without 
precedent. Tacrolimus amorphous solid dispersions (the commercial 
product is Prograf®) are prepared by dissolution of the drug in an or-
ganic solvent, solvent impregnation into the polymer, solvent removal, 
and then blending with additional excipients prior to filling into cap-
sules (Honbo et al., 1987; Trasi et al., 2017; Yamashita et al., 2003). 
The wet granulation approach described herein is attractive since it can 
potentially reduce the number of required processing operations, pro-
ducing granules that can be mixed with a disintegrant and then com-
pressed. 
In terms of dissolution performance, the co-granulated sample in the 
neutral media resulted in lower concentrations of both drugs relative to 
dissolution of single component granules (when dissolved alone), 
whereby the concentration of RTV was depressed more than that of LPV 
(Fig. 3). The reason for the lowered concentration upon dissolution of 
the co-granules is due to the mixing of the two compounds in the 
amorphous solid state, i.e. formation of a co-amorphous system. This 
results in a mutually decreased chemical potential, and thus a lowered 
amorphous solubility of each compound, which also decreases the 
driving force for dissolution, as described in detail previously (Trasi and 
Taylor, 2015b). In other words, mixing the drugs together to form a 
single phase amorphous system, is detrimental to the amorphous so-
lubility of each drug. Further, RTV is affected to a greater extent than 
LPV. This is because the extent of the amorphous solubility reduction 
caused by mixing with a second compound in the amorphous phase is 
dependent on the relative proportions of each compound, with the 
minor component experiencing a greater extent of amorphous solubility 
reduction than the major component. Because RTV it is present in a 
lower amount in the co-granulate (the ratio of LPV:RTV is 4:1), it ex-
periences a greater decrease in chemical potential, consistent with a 
greater extent of dilution in the co-amorphous system brought about by 
mixing with the larger amount of LPV. In other words, molecular 
mixing of both components into a single amorphous phase negatively 
impacts their dissolution performance (Alhalaweh et al., 2016; Trasi 
and Taylor, 2015b), explaining the data presented in Fig. 3. 
While the mutually reduced amorphous solubility explains the 
single step, pH 6.8 dissolution results (Fig. 3), the situation is much 
more complex for two-step dissolution, whereby the pH is initially 
acidic, and then increased to pH 6.8. This is because one of the com-
ponents, RTV, can undergo ionization at low pH. Due to the higher 
solubility of the ionized form, RTV releases from the granules to a much 
higher concentration in acid relative to at neutral conditions. However, 
when the pH increases, RTV solubility decreases due to the change in 
ionization state, with the solution becoming supersaturated. Further, if 
the un-ionized concentration exceeds the amorphous solubility, as in 
this study, liquid liquid phase separation with the formation of amor-
phous nanodroplets occurs (Ilevbare and Taylor, 2013; Sugihara and 
Taylor, 2018). Given that both RTV and LPV are present in the solution 
phase following pH change, mixing of the neutral drug species occurs. 
Mixing between RTV and LPV in the nanodroplets will result in the 
same amorphous solubility (and hence concentration) suppression 
phenomenon described above. This can be clearly seen with the pH 
switching experiments shown in Figs. 5–6, where only the molecularly 
dissolved drug was measured (the precipitated material was removed 
by centrifugation). Under acidic conditions, high RTV concentrations 
are achieved upon dissolution due to ionization, while after the pH 
increase, the molecularly dissolved RTV concentration (i.e. the extent of 
supersaturation) plummets. This decrease can be attributed to three 
factors, 1) a modest dilution factor (25%), 2) a change in ionization 
state which leads to the amorphous solubility being exceeded, and 
hence the formation of a drug-rich phase with the loss of free drug from 
solution and, 3) suppression of RTV amorphous solubility by mixing of 
RTV and LPV in the nanodroplets. 
When the drug release profiles of the co-granulated sample and 
AluviaTM are compared in acidic media, it can be seen that the release 
of RTV is lower from the granules relative to the commercial tablets. It 
is desirable that the release behavior of the drugs prepared using wet 
granulation matches that of the innovator product, therefore it is of 
interest to understand potential causes for the differences. Most likely 
differences in drug:polymer ratios play a part in these observations, 
combined with the solubility suppression phenomenon in the co-
amorphous mixtures. Drug release from an ASD typically falls within 
one of two regimens namely, drug-controlled or polymer-controlled. 
When the polymer is hydrophilic (such as PVPVA), polymer-controlled 
release will result in rapid drug dissolution. On the other hand, in a 
drug-controlled regime, slow drug dissolution would result for a hy-
drophobic drug. Whether the dissolution is drug-controlled or polymer-
controlled depends on the drug-polymer ratio. The drug dissolution 
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Fig. 11. Proposed mechanism for retardation of RTV dissolution from co-
amorphous system with LPV. Dissolution of RTV from the surface of the par-
ticles in acidic media leaves behind a LPV-rich surface which acts as a barrier 
for the remaining RTV to dissolve. 
a milky solution was formed consistent with drug dissolution to above 
the amorphous solubility of each component, followed by liquid liquid 
phase separation and nanodroplet formation. Since nanodroplet for-
mation during dissolution of ASDs is normally seen in the case of low 
drug loading (Purohit and Taylor, 2017), and specifically for RTV-
PVPVA ASDs it has been shown to occur only for dispersions with a 
drug loading less than 25% (Indulkar et al., 2019), it is likely that the 
total drug loading in the marketed formulation is in this range or lower. 
In the wet granulated powders prepared herein, a higher drug loading 
dispersion was prepared (50%) to try and keep the final tablet weight at 
a reasonable value. In this regimen, we expect the drug release to be 
drug-controlled rather than polymer-controlled, based on previous ob-
servations with RTV and PVPVA dispersions (Indulkar et al., 2019). If 
only amorphous RTV was present in the ASD, then the drug release 
would have been fast and complete, since the drug ionizes upon contact 
with the medium and has a high driving force for dissolution. However, 
when present in combination with LPV, we expect the polymer to in-
itially release faster than the drugs, leading to drug enrichment 
(Indulkar et al., 2019). Further, RTV will be preferentially released 
relative to LPV due to its higher solubility, thus the surface will become 
enriched with LPV after the initial release of RTV. At this point, the 
release will be mainly controlled by LPV, which is less soluble in acidic 
media since it does not ionize. This pattern of events is supported by 
evaluation of dispersions with high proportions of RTV, where a greater 
extent of RTV release is observed (Fig. 7). Further, a simple mass bal-
ance consideration supports the contention that LPV becomes enriched 
on the surface of the co-amorphous system after partial dissolution in 
acidic media. The remaining RTV now has to diffuse through a barrier 
layer that is LPV-rich, hindering complete dissolution. This proposed 
mechanism is shown in Fig. 11. 
Since the presence of LPV intimately mixed with RTV resulted in 
retarded RTV release, even under favorable release conditions, i.e. in an 
acidic medium, the best approach appears to be of granulating the two 
drug separately and then either adding disintegrant and mixing prior to 
compaction or to make bi-layered tablets to physically separate the 
drugs. This approach led to much improved dissolution profiles, as 
shown in Fig. 8. Clearly this approach enables each drug to dissolve 
independently and better exploits the ionization of RTV in the acidic 
medium. 
6. Conclusions 
We have demonstrated proof-of-concept for the preparation of 
amorphous solid dispersions using a simple wet granulation approach. 
By dissolving drug(s) and polymer in an organic solvent, and adding to 
an excipient blend, compressible granules can be readily formed. No 
drug crystallinity existed after preparation, and the granules had good 
physical stability under accelerated storage conditions. This approach 
appears best suited for low or moderately low dose drugs, since the 
excipient burden required for this manufacturing method is relatively 
high. When preparing a co-amorphous formulation of ritonavir (minor 
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component) and lopinavir (major component) using this approach, we 
found that the presence of lopinavir in the co-amorphous system de-
pressed the release of ritonavir. This issue could be largely resolved by 
preparing individual ASD granules of each drugs, followed by mixing 
and compaction. Clearly the phase behavior of fixed dose combinations 
of amorphous formulations is highly complex and needs to be con-
sidered when designing the formulation. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper. 
Acknowledgements 
The Bill and Melinda Gates Foundation is acknowledged for funding 
this study through award number OPP1159809. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.ijpx.2019.100035. 
References 
Aisha, A.F.A., Ismail, Z., Abu-Salah, K.M., Majid, A., 2012. Solid dispersions of a-man-
gostin improve its aqueous solubility through self-assembly of nanomicelles. J. 
Pharm. Sci. 101, 815–825. 
Alhalaweh, A., Bergstrom, C.A.S., Taylor, L.S., 2016a. Compromised in vitro dissolution 
and membrane transport of multidrug amorphous formulations. J. Control. Release 
229, 172–182. 
Allesø, M., Chieng, N., Rehder, S., Rantanen, J., Rades, T., Aaltonen, J., 2009. Enhanced 
dissolution rate and synchronized release of drugs in binary systems through for-
mulation: Amorphous naproxen–cimetidine mixtures prepared by mechanical acti-
vation. J. Control. Release 136, 45–53. 
Bevernage, J., Brouwers, J., Brewster, M.E., Augustijns, P., 2013. Evaluation of gastro-
intestinal drug supersaturation and precipitation: strategies and issues. Int. J. Pharm. 
453, 25–35. 
Borbás, E., Sinkó, B., Tsinman, O., Tsinman, K., Kiserdei, É., Démuth, B., Balogh, A., 
Bodák, B., Domokos, A., Dargó, G., Balogh, G.T., Nagy, Z.K., 2016. Investigation and 
mathematical description of the real driving force of passive transport of drug mo-
lecules from supersaturated solutions. Mol. Pharm. 13, 3816–3826. 
Dengale, S.J., Ranjan, O.P., Hussen, S.S., Krishna, B.S.M., Musmade, P.B., Gautham 
Shenoy, G., Bhat, K., 2014. Preparation and characterization of co-amorphous 
Ritonavir-Indomethacin systems by solvent evaporation technique: improved dis-
solution behavior and physical stability without evidence of intermolecular interac-
tions. Eur. J. Pharm. Sci. 62, 57–64. 
Drewe, J., Gutmann, H., Fricker, G., Torok, M., Beglinger, C., Huwyler, J., 1999. HIV 
protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cy-
closporine analog SDZ PSC 833. Biochem. Pharmacol. 57, 1147–1152. 
Frank, K.J., Rosenblatt, K.M., Westedt, U., Holig, P., Rosenberg, J., Magerlein, M., Fricker, 
G., Brandl, M., 2012a. Amorphous solid dispersion enhances permeation of poorly 
soluble ABT-102: True supersaturation vs. apparent solubility enhancement. Int. J. 
Pharm. 437, 288–293. 
Frank, K.J., Westedt, U., Rosenblatt, K.M., Hölig, P., Rosenberg, J., Mägerlein, M., Brandl, 
M., Fricker, G., 2012b. Impact of FaSSIF on the solubility and dissolution-/permea-
tion rate of a poorly water-soluble compound. Eur. J. Pharm. Sci. 47, 16–20. 
Fung, M., Berziņš, K.r., Suryanarayanan, R, 2018. Physical stability and dissolution be-
havior of ketoconazole-organic acid coamorphous systems. Mol. Pharm. 15, 
1862–1869. 
Hancock, B.C., Zografi, G., 1997. Characteristics and significance of the amorphous state 
in pharmaceutical systems. J. Pharm. Sci. 86, 1–12. 
Honbo, T., Kobayashi, M., Hane, K., Hata, T., Ueda, Y., 1987. The oral dosage form of FK-
506. Trans. Proceed. 19, 17–22. 
Ilevbare, G.A., Taylor, L.S., 2013. Liquid-liquid phase separation in highly supersaturated 
aqueous solutions of poorly water-soluble drugs: implications for solubility enhan-
cing formulations. Crys. Growth Des. 13, 1497–1509. 
Indulkar, A.S., Lou, X., Zhang, G.G.Z., Taylor, L.S., 2019. Insights into the dissolution 
mechanism of ritonavir-copovidone amorphous solid dispersions: importance of 
congruent release for enhanced performance. Mol. Pharm. 16, 1327–1339. 
Knapik-Kowalczuk, J., Tu, W., Chmiel, K., Rams-Baron, M., Paluch, M., 2018. Co-
Stabilization of amorphous pharmaceuticals—the case of nifedipine and nimodipine. 
Mol. Pharm. 15, 2455–2465. 
Kothari, K., Ragoonanan, V., Suryanarayanan, R., 2015. The role of drug-polymer hy-
drogen bonding interactions on the molecular mobility and physical stability of ni-
fedipine solid dispersions. Mol. Pharm. 12, 162–170. 
Law, D., Krill, S.L., Schmitt, E.A., Fort, J.J., Qiu, Y., Wang, W., Porter, W.R., 2001. 
8 
N.S. Trasi, et al. International Journal of Pharmaceutics: X 1 (2019) 100035 
Physicochemical considerations in the preparation of amorphous ritonavir–poly 
(ethylene glycol) 8000 solid dispersions. J. Pharm. Sci. 90, 1015–1025. 
Löbmann, K., Laitinen, R., Grohganz, H., Gordon, K.C., Strachan, C., Rades, T., 2011. 
Coamorphous drug systems: enhanced physical stability and dissolution rate of in-
domethacin and naproxen. Mol. Pharm. 8, 1919–1928. 
Loftsson, T., 2017. Drug solubilization by complexation. Int. J. Pharm. 531, 276–280. 
Martinez, L.M., Videa, M., Sosa, N.G., Ramirez, J.H., Castro, S., 2016. Long-term stability 
of new co-amorphous drug binary systems: study of glass transitions as a function of 
composition and shelf time. Molecules 21, 1712. 
Mosquera-Giraldo, L.I., Li, N., Wilson, V.R., Nichols, B.L.B., Edgar, K.J., Taylor, L.S., 
2018. Influence of polymer and drug loading on the release profile and membrane 
transport of telaprevir. Mol. Pharm. 15, 1700–1713. 
Murtomaa, M., Savolainen, M., Christiansen, L., Rantanen, J., Laine, E., Yliruusi, J., 2004. 
Static electrification of powders during spray drying. J. Electrostat. 62, 63–72. 
Paudel, A., Worku, Z.A., Meeus, J., Guns, S., Van den Mooter, G., 2013. Manufacturing of 
solid dispersions of poorly water soluble drugs by spray drying: formulation and 
process considerations. In. J. Pharm. 453, 253–284. 
Planinsek, O., Planinsek, D., Zega, A., Breznik, M., Srcic, S., 2006. Surface analysis of 
powder binary mixtures with ATR FTIR spectroscopy. Int. J. Pharm. 319, 13–19. 
Prasad, D., Chauhan, H., Atef, E., 2014. Amorphous stabilization and dissolution en-
hancement of amorphous ternary solid dispersions: combination of polymers showing 
drug-polymer interaction for synergistic effects. J. Pharm. Sci. 103, 3511–3523. 
Purohit, H.S., Taylor, L.S., 2017. Phase behavior of ritonavir amorphous solid dispersions 
during hydration and dissolution. Pharm. Res. 34, 2842–2861. 
Raina, S., Zhang, G.Z., Alonzo, D., Wu, J., Zhu, D., Catron, N., Gao, Y., Taylor, L., 2015. 
Impact of solubilizing additives on supersaturation and membrane transport of drugs. 
Pharm. Res. 1–15. 
Repka, M.A., Majumdar, S., Battu, S.K., Srirangam, R., Upadhye, S.B., 2008. Application 
of hot-melt extrusion for drug delivery. Exp. Opin. Drug Deliv. 5, 1357–1376. 
Shayanfar, A., Jouyban, A., 2013. Drug-drug coamorphous systems: characterization and 
physicochemical properties of coamorphous atorvastatin with carvedilol and glib-
enclamide. J. Pharm. Innov. 8, 218–228. 
Sugihara, H., Taylor, L.S., 2018. Evaluation of pazopanib phase behavior following pH-
induced supersaturation. Mol. Pharm. 15, 1690–1699. 
Takano, R., Takata, N., Saito, R., Furumoto, K., Higo, S., Hayashi, Y., Machida, M., Aso, 
Y., Yamashita, S., 2010. Quantitative analysis of the effect of supersaturation on in 
vivo drug absorption. Mol. Pharm. 7, 1431–1440. 
Tantishaiyakul, V., Songkro, S., Suknuntha, K., Permkum, P., Pipatwarakul, P., 2009. 
Crystal structure transformations and dissolution studies of cimetidine-piroxicam 
coprecipitates and physical mixtures. AAPS PharmSciTech 10, 789–795. 
Trasi, N.S., Purohit, H.S., Taylor, L.S., 2017. Evaluation of the crystallization tendency of 
commercially available amorphous tacrolimus formulations exposed to different 
stress conditions. Pharm. Res. 34, 2142–2155. 
Trasi, N.S., Taylor, L.S., 2015a. Dissolution performance of binary amorphous drug 
combinations–impact of a second drug on the maximum achievable supersaturation. 
Int. J. Pharm. 496, 282–290. 
Trasi, N.S., Taylor, L.S., 2015b. Thermodynamics of highly supersaturated aqueous so-
lutions of poorly water-soluble drugs—impact of a second drug on the solution phase 
behavior and implications for combination products. J. Pharm. Sci. 104, 2583–2593. 
Wikstrom, H., Carroll, W.J., Taylor, L.S., 2008. Manipulating theophylline monohydrate 
formation during high-shear wet granulation through improved understanding of the 
role of pharmaceutical excipients. Pharm. Res. 25, 923–935. 
Yamashita, K., Nakate, T., Okimoto, K., Ohike, A., Tokunaga, Y., Ibuki, R., Higaki, K., 
Kimura, T., 2003. Establishment of new preparation method for solid dispersion 
formulation of tacrolimus. Int. J. Pharm. 267, 79–91. 
Zhang, W., Perry, K.W., Wong, D.T., Potts, B.D., Bao, J., Tollefson, G.D., Bymaster, F.P., 
2000. Synergistic effects of olanzapine and other antipsychotic agents in combination 
with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. 
Neuropsychopharmacology 23, 250. 
9 
